A study published in Nature Aging claims that the C3 protein calorie restriction connection could point towards drug treatments that replicate some longevity effects of eating less, without requiring people to actually do so. The research, led by Yale School of Medicine, identifies an immune protein called complement component 3 (C3) as a potential target for reducing age-related inflammation. Whether the findings translate into workable treatments remains an open question, but the mechanistic case the team has assembled is more detailed than most.
What the CALERIE trial showed about C3 and calorie restriction
The researchers drew on plasma samples from 42 people who participated in the CALERIE trial, a National Institutes of Health-funded study in which participants reduced their calorie intake by 11 to 14% over two years. Vishwa Deep Dixit, Waldemar Von Zedtwitz Professor of Pathology and director of the Yale Center for Research on Aging, describes CALERIE as “the only trial of its kind that has been done with such rigor and control and demonstrates relevance to human physiology.”
Across those samples, the team measured more than 7,000 proteins, according to ScienceDaily. One stood out: C3, an immune protein whose levels fell after calorie restriction. The complement system, of which C3 is a component, helps the body defend itself against pathogens. Earlier research had suggested that complement activation may also drive chronic inflammation, the persistent, low-grade immune activity widely considered a feature of ageing and many age-related diseases. As SciTechDaily notes, the paper was published on 13 April 2026. The causal role of C3 in that inflammatory process, the team says, had not previously been established.
In humans, the research found that the C3a/C3 ratio was significantly lowered by caloric restriction, a finding reported in the Nature Aging paper itself. C3a is a fragment produced when C3 is activated; a lower ratio suggests less complement activation and, the researchers argue, less inflammatory signalling. Hee-Hoon Kim, a postdoctoral associate in the Dixit lab and a co-first author of the paper, says: “The causal effects of C3 in aging and chronic inflammation have not been identified. So, we were very excited to find that in our study.”
Fat tissue, macrophages and the C3 protein calorie restriction mechanism
The team then worked to identify where the age-related rise in C3 was coming from. Comparing protein levels before and after two years of restriction, they found that white adipose tissue appeared to be the primary tissue affected by the dietary change. That came as a surprise: as Manish Mishra, also a postdoctoral associate in the Dixit lab and a co-first author, notes, “these proteins are mainly synthesized in the liver.” Tests in mice confirmed the pattern, showing that visceral white adipose tissue was a major source of the age-related increase in C3.
Single-cell RNA sequencing narrowed the source further still. C3, the researchers found, was being produced by age-associated macrophages located within adipose tissue. Macrophages are among the immune system’s first responders, best known for engulfing pathogens, but they also play a role in maintaining normal tissue function. Mishra describes the process of identifying the specific macrophage subtypes responsible as “very challenging.”
A further question was whether weight loss itself was driving the decline in C3. Most participants in the CALERIE study lost around 18 pounds after two years of moderate restriction. When the researchers compared changes in body mass index with changes in complement protein levels, however, they found no relationship between the amount of weight lost and the decline in those proteins. Kim says this “suggests that calorie restriction has a beneficial effect that is unique to adipose tissues and is likely independent of weight loss.”
That finding matters for the drug development logic. If lower C3 were simply a consequence of losing fat, shrinking adipose tissue would be doing the work. The absence of a dose-response relationship between weight loss and C3 decline opens the door, at least in principle, to compounds that target the protein directly.
To test that possibility, the team used a drug to inhibit C3 activation in mice, mimicking one effect of calorie restriction. The animals developed less age-related inflammation. Dixit frames the result through the concept of antagonistic pleiotropy, proposed by biologist Peter Medawar in 1952: biological systems that are protective early in life can become harmful later. C3 evolved to defend against infection, but in longer-lived humans, the same mechanism may eventually contribute to disease.
The team is now studying whether FDA-approved inhibitor drugs could suppress C3 production and slow aspects of ageing in humans. The stated goal is not to eliminate the complement system, which remains essential for fighting infections. “The idea is not to remove complement systems that are required for us to fight infections,” Dixit says. “Instead, the goal is to restore the balance.” Whether existing approved drugs can achieve that balance precisely enough is what their current work aims to establish.
